Nivo40-AVD for advanced Hodgkin lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of nivolumab and chemotherapy (AVD) for people newly diagnosed with advanced classic Hodgkin lymphoma. The goal is to see if adding nivolumab improves treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have newly diagnosed advanced classic Hodgkin lymphoma (stages IIB to IV).
- You cannot have a history of autoimmune disease.
- You must be at least 18 years old.
- Your heart's pumping ability (ejection fraction) must be above 50%.
- Your overall health must allow you to be up and about (ECOG 0-4).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a blood test (ctDNA) to guide treatment for Hodgkin lymphoma that has come back or not responded to one prior treatment. You would receive a combination of drugs (pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin) to see if it works better.
This trial tests a newer, lower-dose immunotherapy combination (AVD plus nivolumab) against a standard intensive chemo regimen (BEACOPP) that is adjusted based on PET scan results. It is for people with advanced classical Hodgkin lymphoma that has not been treated before.
This trial tests whether adding the immunotherapy drug nivolumab to the first treatment of advanced Hodgkin lymphoma can improve outcomes. It uses PET scans to guide therapy, potentially reducing the need for stronger chemotherapy.
This study tests a combination of a newer immunotherapy drug (nivolumab) with standard chemotherapy (AVD) in children, teens, and young adults with newly diagnosed, early-stage Hodgkin lymphoma—a blood cancer affecting lymph nodes. The goal is to see if adding immunotherapy improves outcomes while being tolerable for this age group.
This trial tests a combination of two drugs (brentuximab vedotin, AVD chemotherapy) for people with newly diagnosed, bulky Hodgkin lymphoma that hasn't spread far. It aims to see if this treatment works well for larger tumors.
This trial tests whether adding pianzumab to standard AVD chemotherapy works better for newly diagnosed advanced classic Hodgkin lymphoma. It may help people control the cancer and prevent it from coming back, and it will compare outcomes while tracking side effects.
Hear when a new Hodgkin Lymphoma, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.